Revvity management check
RVTY · Health Care · Health Care Equipment · CEO Prahlad R. Singh
Filings as of
4 good · 0 to watch · 2 flagged, across the seven questions below.
- Flag
Have owners done well?
Trailed its chosen peers$100 invested at the start of fiscal 2021 grew to $68, against $105 for the peer group the company picked itself.
- Good
Does pay follow performance?
Pay rose and fell with returnsOver 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.76 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Flag
What does the CEO cost owners?
5.7% of net income$13.8m of reported pay in fiscal 2025, against $241.0m of net income.
- n/a
Do they own the stock?
No recent CEO filingLight activity: no buys, $1.3m sold in six months. 4 of 4 sales ran on pre-arranged 10b5-1 plans.
- Good
Are owners being diluted?
Share count shrinkingDiluted shares changed -3.3% a year over the last three fiscal years. Stock-based pay was 0.8% of revenue in the latest year.
- Good
Is leadership stable?
2 leadership filings in 3 yearsCEO in the pay table: Prahlad R. Singh. 2 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- Good
Are the books clean?
No red flags on fileNo restatements, auditor changes or late filings since 2021.
Against the S&P 500
Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.
| Check | Score | At or above | Sector median |
|---|---|---|---|
| Owner returns | 6 | 26 | |
| Pay for performance | 88 | 85 | |
| CEO cost | 0 | 44 | |
| Skin in the game | — | — | 46 |
| Dilution | 92 | 68 | |
| Stable leadership | 100 | 70 | |
| Clean books | 100 | 100 |
Closest peers
Others in Health Care Equipment, by management score. Revvity is 28th of 60 in its sector.
- 115ABTAbbott Laboratories75
- 149SYKStryker Corporation72
- 156ISRGIntuitive Surgical72
- 188IDXXIdexx Laboratories69
- 192BSXBoston Scientific69
- 246RVTYRevvity64
- 256GEHCGE HealthCare64
- 294RMDResMed62
- 321STESteris60
- 353BDXBecton Dickinson58
Pay versus performance
From the proxy statement filed March 16, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Prahlad R. Singh | $13.8m | $5.8m | $3.9m | $68 | $105 | $241.0m |
| 2024 | — | $11.9m | $11.5m | $2.9m | $79 | $100 | $270.0m |
| 2023 | — | $9.1m | $3.6m | $2.2m | $77 | $104 | $693.0m |
| 2022 | — | $10.6m | $1.8m | $2.1m | $98 | $107 | $569.0m |
| 2021 | — | $9.7m | $22.4m | $2.4m | $140 | $139 | $943.0m |
The board says pay is tied most to Average Non-COVID Organic Revenue Growth. Its other key measures: Adjusted Operating Margin Expansion, Organic Revenue Growth, Adjusted EPS, Free Cash Flow Conversion.
Insiders and the CEO's stake
Light activity: no buys, $1.3m sold in six months. 4 of 4 sales ran on pre-arranged 10b5-1 plans.
- SoldTajinder S VohraPlease See Remarks · 10b5-1 plan$1.0mSep 16, 2026
- SoldMaxwell KrakowiakPlease See Remarks · 10b5-1 plan$236kSep 21, 2026
- SoldAnita GonzalesVP and CAO · 10b5-1 plan$22kOct 1, 2026
Leadership and governance on file
- Oct 24, 2025Leadership change8-K 5.02
- Jan 26, 2024Leadership change8-K 5.02
- Aug 17, 2022Leadership change8-K 5.02
- Jul 22, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 1, 2026, including the say-on-pay vote.
Where the money went
Over 2021–2025: $1.9bn returned to owners in buybacks and dividends, 70% of net income, and $183.3m of pay in stock.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.8bn | $3.3bn | $2.8bn | $2.8bn | $2.9bn |
| Net income | $943.2m | $569.2m | $693.1m | $270.4m | $241.2m |
| Stock-based pay | $29.7m | $51.5m | $41.4m | $37.8m | $22.8m |
| Buybacks | $73.1m | $80.6m | $388.9m | $369.6m | $820.8m |
| Dividends | $32.4m | $35.3m | $35.0m | $34.5m | $32.8m |
| Diluted shares | 117m | 126m | 125m | 123m | 117m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.